Next Article in Journal
Clinical Value and Time Course of Pericoronary Fat Inflammation in Patients with Angiographically Nonobstructive Coronaries: A Preliminary Report
Next Article in Special Issue
A Review of the Role of the Intestinal Microbiota in Age-Related Macular Degeneration
Previous Article in Journal
Clinical History and Detectable Troponin Concentrations below the 99th Percentile for Risk Stratification of Patients with Chest Pain and First Normal Troponin
Previous Article in Special Issue
Age-Related Macular Degeneration (AMD): A View to the Future
Due to scheduled maintenance work on our core network, there may be short service disruptions on this website between 16:00 and 16:30 CEST on September 25th.
Review

Trends of Stem Cell Therapies in Age-Related Macular Degeneration

1
Department of Ophthalmology, Kobe City Eye Hospital, Kobe 650-0047, Japan
2
Laboratory for Retinal Regeneration, RIKEN Center for Biosystems Dynamics Research, Kobe 650-0047, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Joan W. Miller
J. Clin. Med. 2021, 10(8), 1785; https://doi.org/10.3390/jcm10081785
Received: 21 March 2021 / Revised: 6 April 2021 / Accepted: 17 April 2021 / Published: 20 April 2021
Age-related macular degeneration (AMD) is a highly prevalent irreversible impairment in the elderly population worldwide. Stem cell therapies have been considered potentially viable for treating AMD through the direct replacement of degenerated cells or secretion of trophic factors that facilitate the survival of existing cells. Among them, the safety of pluripotent stem cell-derived retinal pigment epithelial (RPE) cell transplantation against AMD, and some hereditary retinal degenerative diseases, has been discussed to a certain extent in clinical studies of RPE cell transplantation. Preparations are in progress for its clinical application. On the other hand, clinical trials using somatic stem cells are also being conducted, though these had controversial outcomes. Retinal regenerative medicine using stem cells is expected to make steady progress toward practical use while new technologies are incorporated from various fields, thereby making the role of ophthalmologists in this field increasingly important. View Full-Text
Keywords: regenerative medicine; retinal pigment epithelium; iPS cell; ES cell; stem cell; age-related macular degeneration; clinical trial; retina; immune reaction; transplantation regenerative medicine; retinal pigment epithelium; iPS cell; ES cell; stem cell; age-related macular degeneration; clinical trial; retina; immune reaction; transplantation
Show Figures

Figure 1

MDPI and ACS Style

Maeda, T.; Sugita, S.; Kurimoto, Y.; Takahashi, M. Trends of Stem Cell Therapies in Age-Related Macular Degeneration. J. Clin. Med. 2021, 10, 1785. https://doi.org/10.3390/jcm10081785

AMA Style

Maeda T, Sugita S, Kurimoto Y, Takahashi M. Trends of Stem Cell Therapies in Age-Related Macular Degeneration. Journal of Clinical Medicine. 2021; 10(8):1785. https://doi.org/10.3390/jcm10081785

Chicago/Turabian Style

Maeda, Tadao, Sunao Sugita, Yasuo Kurimoto, and Masayo Takahashi. 2021. "Trends of Stem Cell Therapies in Age-Related Macular Degeneration" Journal of Clinical Medicine 10, no. 8: 1785. https://doi.org/10.3390/jcm10081785

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop